JP2017507931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507931A5 JP2017507931A5 JP2016550261A JP2016550261A JP2017507931A5 JP 2017507931 A5 JP2017507931 A5 JP 2017507931A5 JP 2016550261 A JP2016550261 A JP 2016550261A JP 2016550261 A JP2016550261 A JP 2016550261A JP 2017507931 A5 JP2017507931 A5 JP 2017507931A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- composition according
- agent
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020144077A JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936168P | 2014-02-05 | 2014-02-05 | |
| US61/936,168 | 2014-02-05 | ||
| PCT/US2015/014687 WO2015120198A1 (en) | 2014-02-05 | 2015-02-05 | Methods and compositions for treating cancer and infectious diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144077A Division JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507931A JP2017507931A (ja) | 2017-03-23 |
| JP2017507931A5 true JP2017507931A5 (https=) | 2018-03-08 |
Family
ID=53778458
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550261A Pending JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A Active JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A Active JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11213583B2 (https=) |
| EP (1) | EP3102233B1 (https=) |
| JP (3) | JP2017507931A (https=) |
| CN (1) | CN105979961B (https=) |
| CA (1) | CA2937035A1 (https=) |
| WO (1) | WO2015120198A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| CA2937035A1 (en) * | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| US20170165364A1 (en) * | 2014-02-21 | 2017-06-15 | Idac Theranostics, Inc. | Therapeutic agent for solid cancer |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| JP6715491B2 (ja) * | 2014-06-11 | 2020-07-01 | Ｉｄａｃセラノスティクス株式会社 | 免疫チェックポイント制御剤の副作用低減方法 |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| CA2969417A1 (en) * | 2014-12-05 | 2016-06-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
| US20180296663A1 (en) * | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| CN119564879A (zh) * | 2015-08-18 | 2025-03-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的组合物、联用及相关方法 |
| AU2016308286B2 (en) | 2015-08-18 | 2022-04-07 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| EP3496707A4 (en) * | 2016-08-09 | 2020-03-25 | Angimmune, LLC | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| EP3705124A4 (en) * | 2017-10-30 | 2021-07-14 | Ube Industries, Ltd. | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH A SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND AN IMMUNOTHERAPEUTIC |
| KR102721494B1 (ko) * | 2018-04-17 | 2024-10-24 | 국립암센터 | 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도 |
| AU2019351273A1 (en) * | 2018-09-27 | 2021-05-20 | Genocea Biosciences, Inc. | Treatment methods |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| EP4061409A4 (en) * | 2019-11-18 | 2023-12-27 | Children's Medical Center Corporation | Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy |
| EP4097142A4 (en) * | 2020-01-30 | 2024-05-22 | Apeximmune Therapeutics Inc. | METHODS AND COMPOSITIONS FOR TREATING CANCER OR VIRAL INFECTION WITH A PLA2G2D ANTAGONIST |
| CN113045661B (zh) | 2021-04-07 | 2022-06-21 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
| CN121001742A (zh) * | 2023-02-06 | 2025-11-21 | Gmp生物技术有限公司 | 用于癌症的mtor治疗剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| GB2302353B (en) | 1995-06-21 | 1998-11-11 | British Gas Plc | Method of filling an excavated opening |
| GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| US7438907B2 (en) | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| AU2005302459A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
| WO2007143212A1 (en) | 2006-06-02 | 2007-12-13 | Ariad Gene Therapeutics, Inc. | Capecitabine combination therapy |
| CA2652924A1 (en) | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating il-22 and il-17 |
| US20080112888A1 (en) | 2006-06-30 | 2008-05-15 | Schering Corporation | Igfbp2 biomarker |
| CN102203132A (zh) * | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010074266A1 (ja) * | 2008-12-26 | 2010-07-01 | 協和発酵キリン株式会社 | 抗cd4抗体 |
| CN102281761A (zh) | 2009-01-14 | 2011-12-14 | 健康研究股份有限公司 | 用于增强免疫应答的方法和含有mTOR抑制剂的组合物 |
| WO2010124498A1 (en) | 2009-04-30 | 2010-11-04 | Beijing Cellonis Biotechnology Co., Ltd | A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine |
| CA3083324A1 (en) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| WO2011139738A2 (en) * | 2010-04-28 | 2011-11-10 | Tenx Biopharma, Inc. | Therapies using zanolimumab to enhance the immune response |
| US9308253B2 (en) | 2011-09-19 | 2016-04-12 | The Johns Hopkins University | Cancer immunotherapy |
| CA2937035A1 (en) | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| AU2015264528A1 (en) * | 2014-05-21 | 2016-11-03 | Kyowa Hakko Kirin Co., Ltd. | Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer |
| EP3229025B1 (en) | 2014-12-02 | 2019-07-17 | The University of Tokyo | Method for assessing therapeutic effect of anti-cancer agent having anti-cd4 antibody as active ingredient |
-
2015
- 2015-02-05 CA CA2937035A patent/CA2937035A1/en active Pending
- 2015-02-05 EP EP15747022.0A patent/EP3102233B1/en active Active
- 2015-02-05 JP JP2016550261A patent/JP2017507931A/ja active Pending
- 2015-02-05 WO PCT/US2015/014687 patent/WO2015120198A1/en not_active Ceased
- 2015-02-05 US US15/116,485 patent/US11213583B2/en active Active
- 2015-02-05 CN CN201580007415.4A patent/CN105979961B/zh active Active
-
2020
- 2020-08-28 JP JP2020144077A patent/JP7328187B2/ja active Active
-
2021
- 2021-11-22 US US17/533,065 patent/US20220152198A1/en active Pending
-
2023
- 2023-08-03 JP JP2023126665A patent/JP7767361B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507931A5 (https=) | ||
| JP2023133525A5 (https=) | ||
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| US20230181605A1 (en) | Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity | |
| EP3407911B1 (en) | Methods and pharmaceutical composition for the treatment of cancer | |
| JP2017501167A5 (https=) | ||
| US12377094B2 (en) | Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies | |
| JP2018507220A (ja) | がんの治療のための方法、組成物、及びキット | |
| RU2017121096A (ru) | Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1 | |
| JP2017537090A5 (https=) | ||
| KR20180105685A (ko) | 투카레솔 또는 이의 유사체를 함유하는 조성물 | |
| JP2019503387A5 (https=) | ||
| US20220265823A1 (en) | Uses of myostatin antagonists, combinations containing them and uses thereof | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| JP2024016209A (ja) | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ | |
| WO2023240082A2 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| JP2023501209A (ja) | 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法 | |
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| US20220025061A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| CN102935228B (zh) | 用于肿瘤治疗的试剂、其用途及方法 | |
| CN113573707A (zh) | 用于治疗癌症的组合产品 | |
| US20250034255A1 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| EP3008089A1 (en) | Combination of cd37 antibodies with chlorambucil | |
| JPWO2023133388A5 (https=) | ||
| WO2018227280A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof |